62 related articles for article (PubMed ID: 3374896)
1. High grade nonHodgkin's lymphoma: management with moderate dose combination chemotherapy.
Palmer MC; Fitzharris BM; Robinson BA; Atkinson CH; Colls BM
N Z Med J; 1988 May; 101(846):255-8. PubMed ID: 3374896
[TBL] [Abstract][Full Text] [Related]
2. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
[TBL] [Abstract][Full Text] [Related]
4. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Qin J; Wollner N
Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
[TBL] [Abstract][Full Text] [Related]
5. Modified MACOP-B chemotherapy for intermediate and high grade non Hodgkins lymphomas.
Gopal R; Nair R; Saikia TK; Soman CS; Dinshaw KA; Advani SH
J Assoc Physicians India; 1994 Oct; 42(10):781-4. PubMed ID: 7533151
[TBL] [Abstract][Full Text] [Related]
6. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
Parlier Y; Gorin NC; Stachowiak J; Najman A; Duhamel G
Sem Hop; 1981 Nov 8-25; 57(41-42):1685-90. PubMed ID: 6272402
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
[TBL] [Abstract][Full Text] [Related]
11. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
13. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin's lymphomas-present status of chemotherapy.
Young CW
Clin Bull; 1975; 5(1):20-3. PubMed ID: 776444
[No Abstract] [Full Text] [Related]
17. [Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
Misset JL; Pouillart P; Amiel JL; Schwarzenberg L; Hayat M; de Vassal F; Musset M; Belpomme D; Jasmin C; Albahary C; Depierre R; Mathé G
Nouv Presse Med; 1975 Dec; 4(44):3117-20. PubMed ID: 768904
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases.
Parlier Y; Gorin NC; Najman A; Stachowiak J; Duhamel G
Cancer; 1982 Aug; 50(3):401-9. PubMed ID: 7046899
[TBL] [Abstract][Full Text] [Related]
19. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein PS; DeVita VT; Hubbard S; Chabner BA; Canellos GP; Berard C; Young RC
Ann Intern Med; 1976 Oct; 85(4):417-22. PubMed ID: 61732
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of non-Hodgkin lymphomas].
Fleischer J
Z Gesamte Inn Med; 1979 Jul; 34(13):173-6. PubMed ID: 94197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
